The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.

The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.

The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.

In some aspects, the present disclosure provides compounds of the formula: ##STR00001##
wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the pain of a patient. These compounds may be used in pain relief and show an improved pharmaceutical profile relative to other commonly used opiates and opioid derivatives.

In some aspects, the present disclosure provides compounds of the formula: ##STR00001##
wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the pain of a patient. These compounds may be used in pain relief and show an improved pharmaceutical profile relative to other commonly used opiates and opioid derivatives.

Provided are: an azepan derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof (in the formula: R.sup.1 represents a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.2 and R.sup.3 are the same as or different from each other, and represent a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.4 and R.sup.5 are the same as or different from each other, and represent a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.6 represents a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.7 and R.sup.8 are the same as or different from each other, and represent a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.9 and R.sup.10 are the same as or different from each other, and represent a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.11 represents a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; A and B differently represent a methyl group, a carbonyl group, etc.; and X represents a nitrogen atom or an N-oxide.).

This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ.sub.1 receptor agonist that also has NMDA antagonist activity.

This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ.sub.1 receptor agonist that also has NMDA antagonist activity.

The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.

The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.